banner
LightNews
lumenbio.bsky.social
Lumen Bioscience
@lumenbio.bsky.social
7 followers 1 following 6 posts
Our patented technology allows us to use the well-known food algae spirulina to deliver therapeutic proteins. 🔬 Accelerating Cures 🌍 Expanding Access
Posts Media Videos Starter Packs
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · 2d
Welcoming Jeff Raikes to our board! https://www.lumen.bio/news/2025/10/08/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics
1 1
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · 4d
Welcoming Erik Anderson as Vice Chairman! The WestRiver Group & Singularity University CEO led our Series C and will help scale our spirulina-based biologics.
www.lumen.bio
1 1
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · Jun 4
How can U.S. drug research maintain its competitive edge? Our CEO Brian Finrow, in collaboration with Sandeep Patel, explores solutions for accelerating American innovation.
Read their analysis here, published in @statnews.com.
www.statnews.com/2025/06/03/u...
4 ideas to kick-start U.S. drug research — and beat China in biotech
“There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising safety,” write Brian Finrow and Sandeep Patel.
www.statnews.com
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · Jun 4
Our CEO Brian Finrow recently sat down with The Bio Report to discuss how Lumen is revolutionizing biologics production using algae (spirulina).

Listen to the full episode here: www.podbean.com/pw/pbblog-e7...
The Bio Report | Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
www.podbean.com
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · Apr 3
Promising news for C. diff patients! 100% of patients with LMN-201 + antibiotics successfully resolved their primary infection, and 95% of participants had no recurrence within 28 days (RePreve Trial sentinel cohort results). www.lumen.bio/2025/04/02/l...

#MedSky
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial - Lumen Bioscience
Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its pioneering spirulina-bas...
www.lumen.bio
2 7
lumenbio.bsky.social
Lumen Bioscience @lumenbio.bsky.social · Apr 3
#medsky #IDsky